6-Hydroxytestosterone | 34442-08-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6-Hydroxytestosterone
• 英文别名: 6-OH testosterone；(8R,9S,10R,13S,14S,17S)-6,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 34442-08-5
• 化学式: C₁₉H₂₈O₃
• 分子量: 304.43
• InChiKey: XSEGWEUVSZRCBC-DXNWCKCOSA-N

物化性质

• 沸点：
  479.8±45.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• [EN] INHIBITORS OF CYTOCHROME P450<br/>[FR] INHIBITEURS DE CYTOCHROME P450
  申请人：GILEAD SCIENCES INC

  公开号：WO2012088156A1

  公开（公告）日：2012-06-28

  The present application provides for a compound of formula I, or a salt thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.

  本申请提供了一种化合物，其具有I式结构，或其盐类，含有此类化合物的组合物，包括施用此类化合物的治疗方法，以及包括与至少一种其他治疗剂联合施用此类化合物的治疗方法。
• [EN] IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE<br/>[FR] COMPOSÉS IMIDAZOLOTHIAZOLES UTILISÉS COMME MODULATEURS DE PROTÉINE KINASES
  申请人：AMBIT BIOSCIENCE CORP

  公开号：WO2010054058A1

  公开（公告）日：2010-05-14

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了用于调节受体激酶活性以及用于治疗、预防或改善由受体激酶介导的疾病或紊乱症状的化合物、组合物和方法。
• [EN] INHIBITORS OF CYTOCHROME P450 (CYP3A4)<br/>[FR] INHIBITEURS DE CYTOCHROME P450 (CYP3A4)
  申请人：GILEAD SCIENCES INC

  公开号：WO2012088178A1

  公开（公告）日：2012-06-28

  The present application provides for a compound of formula I, and related compounds, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.

  本申请提供了一种I式化合物，以及相关化合物，或其药学上可接受的盐、溶剂合物和/或酯，含有这种化合物的组合物，包括给予这种化合物的治疗方法，以及包括给予这种化合物和至少一种额外治疗剂的治疗方法。
• [EN] FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION<br/>[FR] HÉTÉROARYL-PYRIDYL- ET PHÉNYL-BENZÈNESULFONAMIDES CONDENSÉS EN TANT QUE MODULATEURS DU CCR2 POUR LE TRAITEMENT DE L'INFLAMMATION
  申请人：CHEMOCENTRYX INC

  公开号：WO2009009740A1

  公开（公告）日：2009-01-15

  Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

  提供的化合物作为CCR2受体的有效拮抗剂。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR2介导疾病的方法以及作为鉴定CCR2拮抗剂的测定中的对照物。具有以下式（I）或其盐的化合物：其中：R1和R2各自独立地是氢、卤素、C1-8烷基、-CN或C1-8卤代烷基，但至少其中一个是氢以外的；每个R3独立地是氢；R4是氢；R5是卤素或C1-8烷基；R6是氢；X1是CR7、N或NO；X2和X4是N或NO；X3是CR7；X6和X7各自独立地选自CR7、N和NO；每个R7独立地选自氢、卤素、取代或未取代的C2-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、-CN、=O、-NO2、-OR6、-OC（O）R8、-CO2R8、-C（O）R8、-C（O）NR0R8、-OC（O）NR9R8、-NR10C（O）R8、-NR10C（O）NR9R8、-NR9R8、-NR10CO2R8、-SR8、-S（O）R8、-S（O）2R8、-S（O）2NR9R8、-NR10S（O）2R8、取代或未取代的C6-10芳基、取代或未取代的5-至10-成员杂芳基和取代或未取代的3-至10-成员杂环烷基。